Characteristics, treatments and outcomes of patients with acute coronary. Relation of white blood cell count to bleeding and. Anticoagulation and antiplatelet therapy in acute coronary. Atlas acs 2timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. The present analysis is restricted to those pts who continued their background dual antiplatelet therapies during the trial, thus avoiding dilution by pts who did not receive such therapies and.
Rivaroxaban in patients with a recent acute coronary syndrome. Rivaroxaban in patients stabilized after a stsegment. The company said the drug was associated with a statistically significant reduction in the primary composite end. According to first author on the study, dr jessica mega brigham and womens hospital, boston, ma, the phase 3 trial, dubbed atlas acs 2 timi 51, is already up and running with a target. Investigators in the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2. In the atlas acs 2 timi 51 trial, 2,402 patients 15. Results of the highly anticipated atlasacs 2 timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications.
Rivaroxaban in patients stabilized after a stsegment elevation myocardial infarction. Whether that risk can be safely reduced by adding an anticoagulant to post acs therapy was addressed in the atlas acs 2 timi 51 trial, which found that rivaroxaban was associated with a reduction in. A subset of patients had their wbc count measured at baseline. Efficacy and safety data are consistent with results of the. Comparison of two potent antithrombotic regimens in acs.
The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major. Management of rivaroxaban in relation to bodyweight and. In atlas acs 2 timi 51, rivaroxaban reduced cv events in patients pts with a recent acs. Reduction of stent thrombosis in patients with acute.
Relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome from the atlas acs 2 timi 51 trial. Fulltext article available only as a pdf file for download. Findings from the atlas acs 2 timi 51 trial, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Results of the highly anticipated atlas acs 2 timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the. Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome acs patients in the largescale trial atlas acs 2 timi 51. Methods study population the study included patients. This website is a free of charge service from daiichi sankyo europe gmbh. Atlas timi 51 jungwon suh seoul national university, korea potent platelet inhibition is a cornerstone in the management of acute coronary syndrome acs. Gibson cm1, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e. A major subanalysis of the atlas acs 2timi 51 study in 7,817 acs patients with a recent stemi demonstrated that xarelto 2. Rivaroxaban reduces events in atlasacs the british. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial. On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 2 5 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2 timi 51.
The page includes a summary of phase iii clinical trials, an overview of indications under investigation by the different drugs and helpful services for patients and healthcare professionals. The acs pc american and international atlas for windows includes longitudes and latitudes for over 152,000 locations and the clocksetting history of virtually every incorporated or unincorporated city, town, neighborhood, airport, or military base in the u. S in addition, there are longitudes, latitudes, time zones and time changes for over 100,000 places in the world outside the u. Safety and efficacy of rivaroxaban when added to aspirin. Investigators in the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 51 atlas acs 2. Ticagrelor has demonstrated survival benefits for patients with acs and has been recommended as a drug of choice in the current practice guidelines. Rivaroxabanrivaroxaban in subjects with acute coronary syndrome in subjects with acute coronary syndrome c. Atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. In this issue of the journal of the american heart association jaha, gibson and colleagues 10 report a secondary analysis of the efficacy and safety of rivaroxaban 2. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. For full access to this pdf, sign in to an existing account, or purchase an annual subscription. Despite the current standard of prolonged dual antiplatelet therapy with aspirin and a p2y 12 receptor antagonist for patients after an acs, risk for recurrent ischemic cv events remains high.
Rivaroxaban reduced mortality post acute coronary syndrome atlas acs 2 timi 51. Read the atlas acs 2 timi 51 trial and the burden of missing data, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Recent acute coronary syndrome the atlas acs 2 timi 51 trial the second trial of a ntixa t herapy to l ower cardiovascular events in a ddition to standard therapy in s ubjects with. Lowdose rivaroxaban reduced mortality in patients with a. An efficacy and safety study for rivaroxaban in patients. Polish registry of acute coronary syndromes pl acs.
Acute coronary syndrome acs is a serious and life threatening condition. The atlas acs 2 timi 51 trial was conducted to evaluate rivaroxaban together with standard antiplatelet therapy asa alone or asa with clopidogrel or ticlopidine versus standard antiplatelet therapy alone, for the prevention of atherothrombotic events in adult patients with elevated cardiac biomarkers after an acs mega et al. Timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. The pivotal atlas acs 2 timi 51 study proves xarelto 2. Atlas acs2, timi 51 2012 randomized 15,342 patients with recent acs to either twicedaily doses of either 2. Rivaroxaban is the only novel oral anticoagulant oac that has finalised a phase iii clinical trial in acute coronary syndrome acs with a.
The atlas acs 2 timi 51 trial found rivaroxaban reduced the risk for the composite endpoint of death from cardiovascular causes, mi or stroke vs. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. Phase iiiphase iii the pivotal atlas acs 2timi 51 study. Efficacy and safety data for the first 2 years came from the atlas acs 2 timi 51 trial. Longterm probabilities were extrapolated using safety and effectiveness of acetylsalicylic acid data, which was estimated from published literature, assuming constant rates in time.
Rationale and design of the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 51 atlas acs 2timi 51 trial. Events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. The antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. Appraise 2 the second apixaban for prevention of acute ischemic events trial50 atlas acs 2 timi 51 the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial49 atollthe acute stemi treated with primary pci and intravenous.
The atlas acs 2timi 51 study multivu, a cision company. The atlas acs 2timi 51 trial and the burden of missing. The effect of rivaroxaban on myocardial infarction in the. Read rivaroxaban reduces spontaneous and large myocardial infarctions. Atlas acs 2 timi 51 was arandomized, double blinded, placebo controlled trial that enrolled 15,526 subjects with an acs to either placebo or rivaroxaban. Request pdf relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome from the atlas acs 2 timi 51 trial an elevated white blood cell wbc. Methods the atlas acs 2 timi 51 study was a placebocontrolled trial that randomly assigned 15,526 patients with recent acs to receive twicedaily doses of either 2. Rivaroxaban with or without aspirin in stable cardiovascular disease. The present analysis is restricted to those pts who continued their background dual antiplatelet therapies during the trial, thus avoiding dilution by pts who did not receive such therapies and providing a rigorous test of the additive role of rivaroxaban.
296 281 267 819 900 918 603 938 356 1303 506 326 1156 131 894 136 396 1403 165 716 454 1251 777 58 783 890 1516 76 1255 608 1003 1254 1467 889 12 434 1468 1433 1489 62